Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: A study in adjuvant-induced arthritis. (November 2017)
- Record Type:
- Journal Article
- Title:
- Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: A study in adjuvant-induced arthritis. (November 2017)
- Main Title:
- Diclofenac but not celecoxib improves endothelial function in rheumatoid arthritis: A study in adjuvant-induced arthritis
- Authors:
- Verhoeven, Frank
Totoson, Perle
Marie, Christine
Prigent-Tessier, Anne
Wendling, Daniel
Tournier-Nappey, Maude
Prati, Clément
Demougeot, Céline - Abstract:
- Abstract: Background and aims: We aimed at investigating the effect of celecoxib (COX-2 selective inhibitor) and diclofenac (non-selective COX inhibitor) on endothelial function, and at identifying the underlying mechanisms in adjuvant-induced arthritis (AIA). Methods: At the first signs of AIA, diclofenac (5 mg/kg twice a day, i.p), celecoxib (3 mg/kg/day, i.p) or saline (Vehicle) was administered for 3 weeks. Endothelial function was studied in aortic rings relaxed with acetylcholine (Ach) with or without inhibitors of NOS, arginase, EDHF and superoxide anions (O2 −° ) production. Aortic expression of eNOS, Ser1177-phospho-eNOS, COX-2, arginase-2, p22 phox and p47 phox was evaluated by Western blotting analysis. Arthritis scores, blood pressure, glycaemia and serum ADMA levels were measured. Results: Diclofenac and celecoxib significantly reduced arthritis score to the same extent ( p <0.05). As compared to vehicle-treated AIA, celecoxib did not change whereas diclofenac improved endothelial function ( p <0.05) through increased EDHF production, decreased arginase activity and expression, decreased superoxide anions production and expression of p22 phox and p47 phox . Diclofenac but not celecoxib significantly enhanced blood pressure and serum ADMA levels. Glycaemia was unchanged by both treatments. Conclusions: Our study reveals that the effect of NSAIDs on endothelial function cannot be extrapolated from their impact on arthritis severity and suggest that changes inAbstract: Background and aims: We aimed at investigating the effect of celecoxib (COX-2 selective inhibitor) and diclofenac (non-selective COX inhibitor) on endothelial function, and at identifying the underlying mechanisms in adjuvant-induced arthritis (AIA). Methods: At the first signs of AIA, diclofenac (5 mg/kg twice a day, i.p), celecoxib (3 mg/kg/day, i.p) or saline (Vehicle) was administered for 3 weeks. Endothelial function was studied in aortic rings relaxed with acetylcholine (Ach) with or without inhibitors of NOS, arginase, EDHF and superoxide anions (O2 −° ) production. Aortic expression of eNOS, Ser1177-phospho-eNOS, COX-2, arginase-2, p22 phox and p47 phox was evaluated by Western blotting analysis. Arthritis scores, blood pressure, glycaemia and serum ADMA levels were measured. Results: Diclofenac and celecoxib significantly reduced arthritis score to the same extent ( p <0.05). As compared to vehicle-treated AIA, celecoxib did not change whereas diclofenac improved endothelial function ( p <0.05) through increased EDHF production, decreased arginase activity and expression, decreased superoxide anions production and expression of p22 phox and p47 phox . Diclofenac but not celecoxib significantly enhanced blood pressure and serum ADMA levels. Glycaemia was unchanged by both treatments. Conclusions: Our study reveals that the effect of NSAIDs on endothelial function cannot be extrapolated from their impact on arthritis severity and suggest that changes in blood pressure and plasma ADMA levels may not be useful to predict CV risk of NSAIDs in RA. Graphical abstract: Highlights: Diclofenac improved endothelial function in adjuvant induced arthritis. Diclofenac reduced O2 −° production, arginase activity/expression, enhanced EDHF production but not NOS activity/expression. Celecoxib did not improve endothelial function even if it was beneficial on arthritis. … (more)
- Is Part Of:
- Atherosclerosis. Volume 266(2017)
- Journal:
- Atherosclerosis
- Issue:
- Volume 266(2017)
- Issue Display:
- Volume 266, Issue 2017 (2017)
- Year:
- 2017
- Volume:
- 266
- Issue:
- 2017
- Issue Sort Value:
- 2017-0266-2017-0000
- Page Start:
- 136
- Page End:
- 144
- Publication Date:
- 2017-11
- Subjects:
- Non-steroidal anti-inflammatory drugs -- Adjuvant-induced arthritis -- Endothelial dysfunction -- Mechanisms -- Rheumatoid arthritis
Arteriosclerosis -- Periodicals
Electronic journals
616.136 - Journal URLs:
- http://www.sciencedirect.com/science/journal/00219150 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/00219150 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.atherosclerosis.2017.09.033 ↗
- Languages:
- English
- ISSNs:
- 0021-9150
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1765.874000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 5056.xml